Summary
- The Therapeutic Goods Administration (TGA) decided not to register Lecanemab, an Alzheimer’s drug, for use in Australia despite its efficacy in slowing cognitive decline.
- The drug can have fatal consequences and cause swelling or bleeding in the brain.
- The TGA rejected the drug due to safety risks associated with amyloid-related imaging abnormalities (ARIA).
- Dementia Australia CEO expressed disappointment over the decision but highlighted ongoing investment in Alzheimer’s and dementia research.